Revance Expands Botulinum Toxin Assets by Acquiring Intellectual Property (IP) Portfolio
- Portfolio covers diverse and novel indications, compositions and formulations -
- Acquisition expands IP rights into inflammation, pain, dermatologic and neurologic disorders-
"Acquiring BTRX's patent portfolio enhances our ability to develop and commercialize new indications for Revance's unique daxibotulinumtoxinA product candidates," said
"Revance is quickly advancing one of the most differentiated and versatile pipelines of neurotoxin drug product candidates for advancing patient care,"
Revance's journey to market starts with the neurotoxin daxibotulinumtoxinA, the company's highly purified botulinum toxin type A. The TransMTS technology is used in the delivery of botulinum toxin through two novel drug product candidates: DaxibotulinumtoxinA Topical Gel (RT001) which permits needle-free application, and DaxibotulinumtoxinA for Injection (RT002), which is designed to enable targeted administration and long-lasting effect.
Revance is developing RT001 and RT002 for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles, excessive sweating and muscle movement disorders. The company holds worldwide rights for all indications of RT001, RT002 and the TransMTS technology platform. Beyond botulinum toxin, Revance believes the TransMTS technology can be applied to transdermal, mid-dermal, or deep tissue delivery of a variety of other macromolecules. More information on Revance can be found at www.revance.com.
"Revance Therapeutics", TransMTS®, "Remarkable
Science Changes Everything", and the Revance logo are registered trademarks of
A link to the Revance R&D Pipeline can be found here http://www.globenewswire.com/NewsRoom/AttachmentNg/823d637f-d5eb-4526-bb7e-940da820a349
Forward Looking Statements
This press release contains forward-looking statements, including statements related to the BTRX IP portfolio, its potential impact on
Forward-looking statements are subject to risks and uncertainties that could cause actual
results to differ materially from our expectations. These risks and uncertainties include, but are not limited to: the outcome, cost, and timing of our product development activities and clinical trials; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; our ability to obtain and maintain regulatory approval of our drug product candidates; our ability to obtain funding for our operations; our plans to research, develop, and commercialize our drug product candidates; our ability to achieve market acceptance of our drug product candidates; unanticipated costs or delays in research, development, and commercialization efforts; the applicability of clinical study results to actual outcomes; the size and growth potential of the markets for our drug product candidates; our ability to successfully
commercialize our drug product candidates and the timing of commercialization activities; the rate and degree of market acceptance of our drug product candidates; our ability to develop sales and marketing capabilities; the accuracy of our estimates regarding expenses, future revenues, capital requirements and needs for financing; our ability to continue obtaining and maintaining intellectual property protection for our drug product candidates; and other risks. Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in Revance's periodic filings with the Securities and Exchange Commission (the "SEC"), including factors described in the section entitled "Risk Factors" of our annual report on Form 10-K filed March 4, 2016 and quarterly report on Form 10-Q filed
Revance Therapeutics Jeanie Herbert(714) 325-3584 firstname.lastname@example.org Burns McClellan Ami Bavishi(212)213-0006 email@example.com Trade Media: Nadine Tosk (504) 453-8344 firstname.lastname@example.org
News Provided by Acquire Media